The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
The company's current financial score is 6.80, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low.
Key Metrics
The company’s current valuation score is 7.01, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -15.00, which is -291.59% below the recent high of 28.75 and -1911.53% above the recent low of -301.80.
The company’s current earnings forecast score is 7.75, which is lower than the Biotechnology & Medical Research industry's average of 8.01. The average price target for Summit Therapeutics Inc is 34.50, with a high of 42.00 and a low of 12.00.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The company’s current price momentum score is 6.82, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 23.41 and the support level at 16.00, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.21. The latest institutional shareholding proportion is 13.57%, representing a quarter-over-quarter decrease of 86.14%. The largest institutional shareholder is The Vanguard, holding a total of 8.67M shares, representing 1.17% of shares outstanding, with 26.38% decrease in holdings.
The company’s current risk assessment score is 3.94, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is -1.22. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
